Deadline DayOne Accelerator
Date
15.05.2025 23:59 - 23:59
Register
The 3-month hybrid program is designed to support Swiss and international high potential, early-stage ventures at the intersection of healthtech with pharma R&D. In addition to expanding its scope to include TechBio alongside digital health and medtech, the program will now accept 20 instead of 15 startups in the program to refine their value proposition, connect with key industry players, and accelerate their growth. Additionally, a new investor syndicate has been created to provide investment for up to 3 startups from the cohort 3 months post-program. This offer will open in Q1 2026.
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
